Navigation Links
Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients
Date:5/20/2008

ingredient in Perforomist(TM) Inhalation Solution.

Perforomist(TM) Inhalation Solution should not be used in patients with acutely deteriorating COPD or to treat acute symptoms. Acute symptoms should be treated with fast-acting rescue inhalers. Perforomist(TM) Inhalation Solution should not be used with other medications containing LABAs. Do not use more than one nebule twice daily. Perforomist(TM) Inhalation Solution should be used with caution in patients with cardiovascular disorders. Perforomist(TM) Inhalation Solution is not a substitute for inhaled or oral corticosteroids. The safety and efficacy of Perforomist(TM) Inhalation Solution in asthma has not been established.

In COPD clinical trials, the most common adverse events reported with Perforomist(TM) Inhalation Solution were diarrhea, nausea, nasopharyngitis, dry mouth, vomiting, dizziness, and insomnia.

Please see full Prescribing Information, including Boxed Warning, at http://www.perforomist.com or call 800-755-5560 and ask for Customer Service.

About COPD(1)

COPD refers to a number of chronic lung disorders in which the airways to the lungs become narrowed and breathing becomes increasingly difficult. The most common forms of COPD are chronic bronchitis and emphysema and many patients suffer from a combination of the two diseases.

COPD is the fourth leading cause of death in America, behind heart disease, cancer and stroke. Twelve million Americans have been diagnosed with COPD and at least another 12 million have symptoms that have not been diagnosed. COPD is not well understood or recognized -- most Americans have not heard of it, not even those who may be living with the condition. The most common cause of COPD is cigarette smoking, which is responsible for an estimated 80 to 90 percent of COPD cases. Estimates of the total incidence of COPD in America range from 24 to 30 million.

About Nebulizat
'/>"/>

SOURCE Dey, L.P.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone
2. Clinical Trial Data on the Safety and Efficacy of Concomitant Formoterol Fumarate/ Tiotropium Treatment for COPD
3. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
4. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
5. Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination
6. Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%
7. Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
8. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
9. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
10. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
11. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015  Xcelience, a contract development and ... made a structured cash investment in Powdersize, a ... milling, micronization and powder size classification within the ... business while simultaneously adding a complete set of ... capabilities. "As we continue to ...
(Date:7/31/2015)... 2015 Egalet Corporation (Nasdaq: EGLT ... focused on developing, manufacturing and marketing innovative pain ... announced underwritten public offering of 7,666,667 shares of ... of $11.25 per share. The shares of common ... upon the exercise in full by the underwriters ...
(Date:7/31/2015)... and SAN DIEGO , July ... parent company Eisai Co., Ltd. (Headquarters: Tokyo ... "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: San ... Helen Torley , "NASDAQ: HALO") have signed a clinical ... Halaven ® , "eribulin") in combination with Halozyme,s investigational ...
Breaking Medicine Technology:Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6
... Exploratory Clinical Study of its... -- JERUSALEM, September 14, 2010 ... ... ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
... MedAvante, Inc., the leader in centralized expert evaluation ... and Drug Administration (FDA) has approved the first New ... outcome data collected by MedAvante centralized raters. ... company, submitted the NDA for the drug paliperidone palmitate, ...
Cached Medicine Technology:Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule 2Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule 3Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule 4Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule 5Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule 6Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule 7FDA Approves NDA That Includes Psychiatric Data Collected by Centralized Raters 2FDA Approves NDA That Includes Psychiatric Data Collected by Centralized Raters 3
(Date:8/1/2015)... , ... August 01, 2015 , ... Tina Wilcoxson, owner ... , Wilcoxson was given that honor by the National Retail Federation, the largest retail ... Wilcoxson was one of three Maine business owners to be named as such. According ...
(Date:8/1/2015)... ... August 01, 2015 , ... Lume Wellness creators Alex, Robert, ... to download on the Apple AppStore. , The app is designed to track ... acting as a tool to view personal health and use this information for positive ...
(Date:7/31/2015)... Santa Rosa, CA (PRWEB) , ... July 31, ... ... been posted by High Times magazine. What are the STASH awards? The ... celebrate advances made by the cannabis-cultivation community as well as tried-and-true products that ...
(Date:7/31/2015)... ... ... 50 will emanate from Levi’s Stadium in Santa Clara, CA on Sunday, February 7, ... the two weeks that separate the conference championships and the Super Bowl, there is plenty ... mark the 50th time it has been held and the festivities will take place at ...
(Date:7/31/2015)... ... July 31, 2015 , ... Last week, the ... The store can be accessed by visiting http://www.curemeso.org/store . , “Our new ... The best part: whenever a product is purchased, the Meso Foundation receives a ...
Breaking Medicine News(10 mins):Health News:Local Retail Advocate Wins National Recognition 2Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3
... Insomnia is common in Spain, and affects one person in ... out by the Vall d,Hebron University Hospital in Barcelona and ... 40% of survey respondents aged over 65 report interrupted sleep ... "Good sleep hygiene is necessary in order to avoid primary ...
... 2010 was the discovery of a "golden ratio" in ... forth the new suggestion that matter on the quantum ... opposed to chaos. Stories on the health sciences ... in 2010. The most popular topics varied from neurological ...
... , WEDNESDAY, March 23 (HealthDay News) -- Reducing ... 80 hours a week has not had a negative effect ... training of new doctors, a new study contends. The ... from the United States and United Kingdom, challenge concerns expressed ...
... every year there are reports of a young, apparently healthy athlete ... of Wes Leonard, a junior at Fennville High School, who died ... have parents and coaches wondering if enough is being done to ... to develop a better screening program to help prevent sudden cardiac ...
... Anderson Cancer Center has been awarded a grant to study ... neck cancer radiation treatment, can be prevented when acupuncture is ... grant awarded by the National Cancer Institute (NCI) for the ... peer scientists evaluating grant proposals for NCI. Lorenzo Cohen, ...
... -- The death rate of patients with chronic myeloid leukemia ... treatment was similar to the death rate in the general ... on 832 patients who were taking Gleevec (imatinib) for up ... the follow-up period. That death rate of 4.8 percent, however, ...
Cached Medicine News:Health News:1 in every 5 Spaniards suffers from insomnia 2Health News:Physics story tops EurekAlert!'s 2010 list of most-visited releases 2Health News:Physics story tops EurekAlert!'s 2010 list of most-visited releases 3Health News:Physics story tops EurekAlert!'s 2010 list of most-visited releases 4Health News:Physics story tops EurekAlert!'s 2010 list of most-visited releases 5Health News:Do all student athletes need heart screenings? 2Health News:Do all student athletes need heart screenings? 3Health News:UT MD Anderson receives grant for study of acupuncture in cancer 2Health News:Leukemia Patients Taking Gleevec Achieve 'Normal' Death Rate 2
Stainless steel bone clamp....
Reduction Forceps with Points for precise reduction of bone fragments with minimal soft tissue contact....
Designed for proximal femoral elevation in total hip replacement or in other surgery with a similar need for bone manipulation....
Straight double action bone cutting rongeur....
Medicine Products: